Forget Aurora Cannabis (TSX:ACB): Buy This Marijuana Stock Instead

Here is why Green Thumb Industries Inc (CNSX:GTII) is an excellent cannabis stock to consider buying.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The marijuana sector presents a rare opportunity for investors. With sales and revenues going through the roof, some companies will win big in the future and reward their shareholders in the process. However, many others will be losers, and it isn’t easy to know which is which at the moment.

Some investors looking to profit from this opportunity turn their attention to the companies with the most brand recognition, such as Aurora Cannabis (TSX:ACB)(NYSE:ACB).

But while Aurora and other brand names might be worth considering, slightly lesser-known pot firms are often stronger picks. Let’s consider one mid-cap marijuana company that looks very promising: Green Thumb Industries Inc (CNSX:GTII). 

A rapidly expanding presence south of the border

Despite Canada having more welcoming marijuana laws, the U.S. is the largest cannabis market in the world. Green Thumb has already built a presence in the U.S., including in the single most populated U.S. state, namely California.

The Golden State is one of the dozen (or so) in which both medical and recreational uses of pot are legal. Green Thumb also operates in its home state of Illinois, which happens to be one of the latest states to legalize recreational marijuana.

Overall, Green Thumb operates across 12 US states, has over 30 stores and 13 manufacturing facilities, and holds licenses for 95 retail locations. With plans to open even more new stores by year-end, the company’s presence will likely continue growing. 

Recent financial results 

Green Thumb’s financial results look competitive by industry’s standard. During its latest reported quarter — Q2 2019 — Green Thumb posted revenues of about $44.7 million — a more than 220% increase year over year.

The company’s gross profit margin also increased to 52%, up from 46% year over year. Sequentially, Green Thumb’s revenues increased by about 60% and its gross profit margin grew by 5%.

Note that for the second quarter in a row, the company was able to post record high revenue figures, and its sequential revenue growth was unprecedented. Green Thumb pointed to several factors to explain this performance, including increasing store traffic and a few strategic acquisitions. 

Like many of its peers, though, Green Thumb isn’t yet consistently profitable. The Illinois-based marijuana firm posted a net EBITDA loss of $9.4 million, although adjusted EBITDA was a net profit of $5 million.

Finally, the company posted a net loss of $22.2 million, compared to a net income of just under $400,000 during last year’s corresponding quarter. This net loss was due, among other things, to an increase in operating expenses; it also came slightly below most analyst estimates.

Despite its ugly bottom line, Green Thumb’s quarter was solid. In particular, its growing retail presence and the increasing demand for its products should appeal to investors. 

The bottom line

Investing in any pure play cannabis company carries a somewhat significant amount of risk at the moment. However, some companies seem better equipped than others to profit from the growth of the marijuana sector.

With solid (and growing) footprints in the largest market in the world and strong top line growth, Green Thumb looks relatively attractive right now. Of course, a lot can still go wrong, but those interested in investing in pot stocks should strongly consider Green Thumb Industries. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Junior Bakiny owns shares of Aurora Cannabis.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »